Currently viewing the tag: "BioPorto"
Guest Nina 8:56 AM 03/01/2014 aftale med abbott investor1989 8:57 AM 03/01/2014 Vilkårene for aftalerne omfatter upfront betalinger og royalties vedr. salg for begge parter. BioPorto forventer, at aftalernes direkte virkning på salg og indtægter vil være begrænset i 2014, da de igangværende bestræbelser på at skabe et kommercielt marked for NGAL først skal give […]
I forbindelse med EPO’s “intention to grant” af NGAL eksklusionspatentet kan det være at det er tiden med en lille update på patentsituationen.
Hvis vi ser på eksklusionspatentet først, så må jeg indrømme at det er overraskende at Bioporto har fået det, da den ansøgning har levet et liv på kanten fra først færd af. […]
er der her lige et run-down over nogle af de finansieringsmuligheder BioPorto har – bestemt ikke udtømmende – og der må gerne (meget gerne) kommenteres/rettes – så be my Guest. det er et såkaldt “work in progress” – jeg retter gerne 🙂
Opgaven er at skaffe de 25-30 millioner kroner som BioPorto – ifølge egen […]
Efter en slumrende tilværelse som “formentlig ikke patenterbar patentansøgning” har: “Diagnostic test to exclude significant renal injury” ansøgningen (bedre kendt som “ekslusions ansøgningen”) måske alligevel vist sig at indeholde potentiale.
7. September 2012 meddeler EPO at ansøgingen ikke kan godkendes, og at Bioporto får 4 måneder til at rette henvendelse hvis de alligevel mener, at […]
On october 12th 2012 Alere was granted a USpatent on Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
as the abstract says :
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to […]
interesting article about CKD stemming from West Nile Virus, and how measurement of NGAL levels can possibly help in detecting this. With the ONLY reliable and precise NGAL -test with supreme linearity BioPorto may jus have the ideal tool for that.
To my knowledge it is the first time NGAL is mentioned in a proposed […]
After a hectic day – its time for a little soulsearching. I have no shares in TopoTarget, but that’s just a coincidence, I might as well have had; but basically I am always a little wary with “one-trick-pony’s “- especially biotech-ponies –
Relying on just one product-line is dangerous, it’s 100% make/break … But after todays […]
Bioporto has filed for more US patents, all related to measurement of NGAL. One thing strikes you when you look at the various applications.
Take a look for yourself – if at first you don´t see the common denominator scroll down
Exclusion patent.
The ratio patent:
The CutOff patent:
scroll […]
“When – oh when – will we see a Distribution Agreement ? ” This must have been the most prominent question on the minds of BioPorto-shareholders this year.
Looking at the debates/discussions/polls here on MI – (The Lesser Evil) it certainly has been the predominant topic (apart from OD and EPO)
One could of […]
NGAL measurement has a role to play in detecting AKI after Liver Transplantations. In a very interesting article found on Bioporto.com Taiwanese doctos have looked into that relationship.
Measurements in Taiwan are done using the NGALTest from BioPort (amongst others)
Concentrations of sCr and urinary creatinine (uCr) were measured using the Jaffe kinetic method […]
Ongoing debate
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Thomas Goldberg on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Spekulant.dk on dashboard
- Muldyr on dashboard
- kasperlindvig on dashboard
